Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
暂无分享,去创建一个
[1] M. Civera,et al. Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction. , 2016, Journal of medicinal chemistry.
[2] J. Stebbing,et al. Gene of the month: Axl , 2016, Journal of Clinical Pathology.
[3] D. Arosio,et al. Advancement in integrin facilitated drug delivery. , 2016, Advanced drug delivery reviews.
[4] Stephen T. C. Wong,et al. EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.
[5] V. LeBleu,et al. EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.
[6] E. Colvin,et al. The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle , 2015, Front. Oncol..
[7] V. Beral,et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.
[8] E. Burandt,et al. E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer , 2015, British Journal of Cancer.
[9] A. Tomassetti,et al. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome , 2015, Oncotarget.
[10] T. Regad. Targeting RTK Signaling Pathways in Cancer , 2015, Cancers.
[11] G. Samimi,et al. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models , 2015, Scientific Reports.
[12] Laura Belvisi,et al. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists. , 2015, Chemistry.
[13] N. Cordes,et al. Focal adhesion signaling and therapy resistance in cancer. , 2015, Seminars in cancer biology.
[14] D. Cheresh,et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. , 2015, Trends in cell biology.
[15] L. Monti,et al. Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase , 2015, Oncotarget.
[16] M. Civera,et al. Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. , 2015, Organic & biomolecular chemistry.
[17] O. Shoseyov,et al. Human recombinant truncated RNASET2, devoid of RNase activity; A potential cancer therapeutic agent , 2014, Oncotarget.
[18] J. George,et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. , 2014, The Journal of clinical investigation.
[19] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[20] S. Tsao,et al. p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/β1 integrin signaling activation , 2014, Oncotarget.
[21] Prahlad T. Ram,et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.
[22] Xiuwen Wang,et al. Construction and characteristics of an E-cadherin-related three-dimensional suspension growth model of ovarian cancer , 2014, Scientific Reports.
[23] Gang Li,et al. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. , 2014, Oncology reports.
[24] S. Kellouche,et al. Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins , 2014, Clinical & Experimental Metastasis.
[25] Tuan Zea Tan,et al. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer , 2014, Oncogene.
[26] M. Takeichi. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling , 2014, Nature Reviews Molecular Cell Biology.
[27] S. Ko,et al. P-Cadherin Promotes Ovarian Cancer Dissemination Through Tumor Cell Aggregation and Tumor–Peritoneum Interactions , 2014, Molecular Cancer Research.
[28] S. Kellouche,et al. Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. , 2014, Experimental cell research.
[29] N. Yousif. Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK–PI3K/Akt pathway , 2014, Cell biology international.
[30] Yan Zhou,et al. Effective Inhibition of c-MET-mediated Signaling, Growth, and Migration of Ovarian Cancer Cells is Influenced by the Ovarian Tissue Microenvironment , 2013, Oncogene.
[31] Andrew J. Ewald,et al. Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program , 2013, Cell.
[32] N. Ahmed,et al. Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..
[33] D. Goldstein,et al. Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer , 2013, BioMed research international.
[34] L. Monti,et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis , 2013, Proceedings of the National Academy of Sciences.
[35] A. Whittemore,et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. , 2013, International journal of epidemiology.
[36] C. Lim,et al. Tumor dissemination: an EMT affair. , 2013, Cancer cell.
[37] S. Kaye,et al. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.
[38] Pei Wang,et al. Antitumor Activity of Antimicrobial Peptides Containing CisoDGRC in CD13 Negative Breast Cancer Cells , 2013, PloS one.
[39] L. Belvisi,et al. Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. , 2012, Journal of medicinal chemistry.
[40] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[41] K. Shen,et al. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. , 2012, Cancer epidemiology.
[42] A. Tomassetti,et al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer , 2012, Oncogene.
[43] Andrew J Ewald,et al. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium , 2012, Proceedings of the National Academy of Sciences.
[44] F. Vasile,et al. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. , 2012, Bioconjugate chemistry.
[45] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[46] M. Civera,et al. Synthesis of Gd and 68Ga Complexes in Conjugation with a Conformationally Optimized RGD Sequence as Potential MRI and PET Tumor‐Imaging Probes , 2012, ChemMedChem.
[47] Shan Xu,et al. E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway , 2012, Acta Pharmacologica Sinica.
[48] V. Korshunov. Axl-dependent signalling: a clinical update. , 2012, Clinical science.
[49] E. Kohn,et al. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome , 2012, Cancer.
[50] O. Blaschuk. Discovery and development of N-cadherin antagonists , 2012, Cell and Tissue Research.
[51] K. Sawada,et al. Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer , 2011, Journal of oncology.
[52] Laura Belvisi,et al. A new optical imaging probe targeting αVβ3 integrin in glioblastoma xenografts. , 2011, Contrast media & molecular imaging.
[53] J. Heino,et al. Cooperation between integrins and growth factor receptors in signaling and endocytosis. , 2011, Annual review of cell and developmental biology.
[54] N. Bertos,et al. Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.
[55] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[56] W. Ou,et al. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation , 2011, Molecular Cancer.
[57] J. Guan,et al. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.
[58] Gaudenz Danuser,et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. , 2011, Cancer discovery.
[59] P. Leung,et al. P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin , 2011, Oncogene.
[60] Hiroki Oda,et al. Structural and functional diversity of cadherin at the adherens junction , 2011, The Journal of Cell Biology.
[61] D. Armstrong,et al. Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.
[62] Merrick I Ross,et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[64] C. Desimone,et al. Ten-Year Relative Survival for Epithelial Ovarian Cancer , 2011, Obstetrics and gynecology.
[65] Jiri Bartek,et al. Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity , 2011, PloS one.
[66] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[67] G. Daskalopoulos,et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. , 2010, Chest.
[68] E. Lengyel,et al. Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.
[69] Kevin Wei,et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. , 2010, Cancer research.
[70] F. Carreiras,et al. Mesothelial vitronectin stimulates migration of ovarian cancer cells , 2010, Cell biology international.
[71] P. Leung,et al. Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer , 2010, Oncogene.
[72] A. Sood,et al. Combined anti-angiogenic therapy against VEGF and integrin alphabeta in an orthotopic model of ovarian cancer , 2009, Cancer biology & therapy.
[73] M. Civera,et al. Cyclic RGD‐Containing Functionalized Azabicycloalkane Peptides as Potent Integrin Antagonists for Tumor Targeting , 2009, ChemMedChem.
[74] A. Mancuso,et al. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] G. Castellano,et al. Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. , 2008, Neoplasia.
[76] Liz Y. Han,et al. Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer , 2008 .
[77] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[78] Karen D. Cowden Dahl,et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. , 2008, Cancer research.
[79] P. Febbo,et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. , 2008, Cancer research.
[80] F. Bussolino,et al. Besides adhesion: new perspectives of integrin functions in angiogenesis. , 2008, Cardiovascular research.
[81] E. Kistner,et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. , 2008, Cancer research.
[82] A. Baron,et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.
[83] Ie-Ming Shih,et al. Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[84] W. Nelson,et al. Localized zones of Rho and Rac activities drive initiation and expansion of epithelial cell–cell adhesion , 2007, The Journal of cell biology.
[85] G. Rice,et al. α2β1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis , 2007, Journal of Carcinogenesis.
[86] D. Fishman,et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. , 2007, Cancer research.
[87] A. Yap,et al. Rac is a dominant regulator of cadherin-directed actin assembly that is activated by adhesive ligation independently of Tiam1. , 2007, American journal of physiology. Cell physiology.
[88] E. Kistner,et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.
[89] O. Shoseyov,et al. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics , 2006, Cancer.
[90] R. Agarwal,et al. Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.
[91] D. Schlaepfer,et al. Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.
[92] A. Citri,et al. EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.
[93] Yan Ning,et al. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. , 2005, Cancer research.
[94] H. Beug,et al. Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.
[95] Yan Shen,et al. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. , 2005, Molecular endocrinology.
[96] J. Boyd,et al. Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.
[97] B. de Strooper,et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[98] A. Skubitz,et al. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers , 2005, Clinical & Experimental Metastasis.
[99] L. Monti,et al. Tumor and metastasis suppression by the human RNASET2 gene. , 2005, International journal of oncology.
[100] A. Rustgi,et al. No one-way street: Cross-talk between E-cadherin and receptor tyrosine kinase (RTK) signaling—A mechanism to regulate RTK activity , 2005, Cancer biology & therapy.
[101] T. Shiozawa,et al. Elevated expression of E-cadherin and α-, β-, and γ-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas , 2004 .
[102] T. Tamaya,et al. Coexpression of Gas6/Axl in Human Ovarian Cancers , 2004, Oncology.
[103] Ralph S Freedman,et al. Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC) , 2004, Journal of Translational Medicine.
[104] L. Moro,et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. , 2004, Biochemical Society transactions.
[105] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[106] Douglas R Lowy,et al. E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases , 2004, The EMBO journal.
[107] Albert B. Reynolds,et al. A core function for p120-catenin in cadherin turnover , 2003, The Journal of cell biology.
[108] Keith R. Johnson,et al. Cadherin-mediated cellular signaling. , 2003, Current opinion in cell biology.
[109] K. Münstedt,et al. Association between fibronectin expression and prognosis in ovarian carcinoma. , 2003, Anticancer research.
[110] C. Maccalman,et al. Cadherin switching in ovarian cancer progression , 2003, International journal of cancer.
[111] B. Gumbiner,et al. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin , 2003, The Journal of cell biology.
[112] E. van Marck,et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.
[113] G. Nemerow,et al. Differential regulation of cell motility and invasion by FAK , 2003, The Journal of cell biology.
[114] G. Serban,et al. A presenilin‐1/γ‐secretase cleavage releases the E‐cadherin intracellular domain and regulates disassembly of adherens junctions , 2002, The EMBO journal.
[115] T. P. Pretlow,et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon , 2002, Gut.
[116] C. Tacchetti,et al. Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines* , 2002, The Journal of Biological Chemistry.
[117] E. Kovacs,et al. E-cadherin Homophilic Ligation Directly Signals through Rac and Phosphatidylinositol 3-Kinase to Regulate Adhesive Contacts* , 2002, The Journal of Biological Chemistry.
[118] G. Rice,et al. Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade , 2002 .
[119] Kozo Kaibuchi,et al. Rho-family GTPases in cadherin-mediated cell — cell adhesion , 2001, Nature Reviews Molecular Cell Biology.
[120] F. Giancotti,et al. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes , 2001, The Journal of Cell Biology.
[121] N. Hacker,et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. , 2001, Journal of the National Cancer Institute.
[122] P. Comoglio,et al. Pathway specificity for Met signalling , 2001, Nature Cell Biology.
[123] K. Kaibuchi,et al. Recruitment and activation of Rac1 by the formation of E-cadherin-mediated cell-cell adhesion sites. , 2001, Journal of cell science.
[124] David I. Smith,et al. Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27 , 2001, Oncogene.
[125] D. Sacks,et al. E-cadherin-mediated Cell-Cell Attachment Activates Cdc42* , 2000, The Journal of Biological Chemistry.
[126] A. P. Soler,et al. P‐cadherin expression in breast carcinoma indicates poor survival , 1999, Cancer.
[127] G. Fleuren,et al. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. , 1999, The American journal of pathology.
[128] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[129] L. Silengo,et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival , 1998, The EMBO journal.
[130] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[131] Worsley,et al. Expression of E‐cadherin, α‐catenin and β‐catenin in normal ovarian surface epithelium and epithelial ovarian cancers , 1998 .
[132] J. Scoazec,et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. , 1997, Human pathology.
[133] S. Enerbäck,et al. E‐cadherin expression in human epithelial ovarian cancer and normal ovary , 1997, International journal of cancer.
[134] H. Fujiwara,et al. Inhibition of Growth and Metastasis of Ovarian Carcinoma by Administering a Drug Capable of Interfering with Vascular Endothelial Growth Factor Activity , 1996, Japanese journal of cancer research : Gann.
[135] Peter D. Kwong,et al. Structural basis of cell-cell adhesion by cadherins , 1995, Nature.
[136] T. Hunter,et al. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.
[137] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[138] D. Wheatley,et al. AN ELECTRON MICROSCOPIC STUDY OF THE INVASION OF ASCITES TUMOR CELLS INTO THE ABDOMINAL WALL. , 1965, Cancer research.
[139] M. Dewhirst,et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. , 2015, Annals of surgery.
[140] Alexander Gheldof,et al. Cadherins and epithelial-to-mesenchymal transition. , 2013, Progress in molecular biology and translational science.
[141] P. Leung,et al. Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[142] J. Blaakaer,et al. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. , 2012, Gynecologic oncology.
[143] K. Brown,et al. Synthesis and Biological Evaluation of a Peptide Paclitaxel Conjugate Which Targets the Integrin α v β 6 , 2011 .
[144] M. Stack,et al. Microenvironmental regulation of ovarian cancer metastasis. , 2009, Cancer treatment and research.
[145] M. Hollingsworth,et al. ADH‐1 suppresses N‐cadherin‐dependent pancreatic cancer progression , 2008, International journal of cancer.
[146] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[147] B. Strooper,et al. ADAM 10 mediates E-cadherin shedding and regulates epithelial cell – cell adhesion , migration , and-catenin translocation , 2005 .
[148] M. Mareel,et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.
[149] H. Barr,et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.
[150] H. Sakahara,et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. , 1997, British Journal of Cancer.
[151] E Ruoslahti,et al. RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.